LLY

821.04

-0.03%↓

UNH

516.91

+0.47%↑

JNJ

163.76

+0.38%↑

ABBV

205.38

+1.34%↑

NVO

69.36

-1.14%↓

LLY

821.04

-0.03%↓

UNH

516.91

+0.47%↑

JNJ

163.76

+0.38%↑

ABBV

205.38

+1.34%↑

NVO

69.36

-1.14%↓

LLY

821.04

-0.03%↓

UNH

516.91

+0.47%↑

JNJ

163.76

+0.38%↑

ABBV

205.38

+1.34%↑

NVO

69.36

-1.14%↓

LLY

821.04

-0.03%↓

UNH

516.91

+0.47%↑

JNJ

163.76

+0.38%↑

ABBV

205.38

+1.34%↑

NVO

69.36

-1.14%↓

LLY

821.04

-0.03%↓

UNH

516.91

+0.47%↑

JNJ

163.76

+0.38%↑

ABBV

205.38

+1.34%↑

NVO

69.36

-1.14%↓

Search

Anavex Life Sciences Corp

Closed

SectorHealthcare

8.71 -8.7

Overview

Share price change

24h

Current

Min

8.59

Max

8.78

Key metrics

By Trading Economics

Income

-491K

-12M

EPS

-0.14

Employees

42

EBITDA

-1.8M

-14M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+226.83% upside

Dividends

By Dow Jones

Next Earnings

8 May 2025

Market Stats

By TradingEconomics

Market Cap

813M

Previous open

17.41

Previous close

8.71

News Sentiment

By Acuity

50%

50%

145 / 386 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Anavex Life Sciences Corp Chart

Past performance is not a reliable indicator of future results.

Related News

30 Mar 2025, 23:43 UTC

Market Talk

Gold Edges Higher, Supported by Looming U.S. Tariffs -- Market Talk

30 Mar 2025, 23:41 UTC

Market Talk

Global Equities Roundup: Market Talk

30 Mar 2025, 23:41 UTC

Market Talk

Nikkei May Fall Amid Concerns About U.S. Tariffs, Borrowing Costs -- Market Talk

30 Mar 2025, 23:12 UTC

Earnings

Tsingtao Brewery 2024 Net CNY4.34B Vs. Net CNY4.27B >0168.HK

30 Mar 2025, 23:12 UTC

Earnings

Tsingtao Brewery Board Proposes Final Dividend of CNY2.20/Share >0168.HK

30 Mar 2025, 23:12 UTC

Earnings

Tsingtao Brewery 2024 Rev CNY32.14B Vs. CNY33.94B >0168.HK

30 Mar 2025, 22:30 UTC

Earnings

Great Wall Motor 2024 Net CNY12.69 Vs. Net CNY7.02B >2333.HK

30 Mar 2025, 22:30 UTC

Earnings

Great Wall Motor: Higher Overseas Vehicle Sales Among Factors Supporting Results >2333.HK

30 Mar 2025, 22:30 UTC

Earnings

Great Wall Motor 2024 Rev CNY202.20B Vs. CNY173.21B >2333.HK

30 Mar 2025, 21:44 UTC

Market Talk

Barclays Favors Core Bonds Over Equities as Tariffs Loom -- Market Talk

30 Mar 2025, 21:24 UTC

Market Talk

Early Polling Shows Labor's Support Firms Before Australia Vote -- Market Talk

30 Mar 2025, 21:23 UTC

Top News

Trump Team Weighs Broader, Higher Tariffs -- WSJ

30 Mar 2025, 16:23 UTC

Top News

Tesla's EV Credit Income Is Still Rolling In -- for Now -- Barrons.com

30 Mar 2025, 09:30 UTC

Top News

The AI Data-Center Boom Is Coming to America's Heartland -- WSJ

30 Mar 2025, 09:30 UTC

Top News

Tariffs on Screws Are Already Hitting Manufacturers -- WSJ

29 Mar 2025, 13:00 UTC

Top News

Trump's Trade War Arrives in America's Heartland -- WSJ

29 Mar 2025, 11:00 UTC

Top News

Selling Your House This Spring? You Might Need to Cut the Price -- Heard on the Street -- WSJ

29 Mar 2025, 09:30 UTC

Top News

The Auto Union Boss Who Went From Trump Foe to Tariff Cheerleader -- WSJ

29 Mar 2025, 08:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

29 Mar 2025, 08:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

29 Mar 2025, 00:00 UTC

Top News

The Drone-Delivery Service Beating Amazon to Your Front Door -- WSJ

28 Mar 2025, 23:16 UTC

Acquisitions, Mergers, Takeovers

CoreWeave Debuts: A Big IPO in a Slow Year -- Barrons.com

28 Mar 2025, 22:21 UTC

Top News

Inflation, Consumer Fears Fuel Stock Selloff -- WSJ

28 Mar 2025, 21:49 UTC

Top News

FCC Investigates Disney for DEI Practices, Chair Says -- 2nd Update

28 Mar 2025, 21:28 UTC

Top News

Stocks Fall on Tariff, Consumer Sentiment Fears -- WSJ

28 Mar 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

28 Mar 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

28 Mar 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

28 Mar 2025, 20:40 UTC

Top News

OpenAI's Latest Funding Round Comes With a $20 Billion Catch -- WSJ

28 Mar 2025, 20:36 UTC

Top News

Consumers' Mood Sours in March With Gloomier Economic Outlook -- 4th Update

Peer Comparison

Price change

Anavex Life Sciences Corp Forecast

Price Target

By TipRanks

226.83% upside

12 Months Forecast

Average 28.5 USD  226.83%

High 42 USD

Low 15 USD

Based on 2 Wall Street analysts offering 12 month price targets forAnavex Life Sciences Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

2

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

N/A / 9.31Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Neutral Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

145 / 386 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Interest expense on debt

EBITDA

Operating profit

$

About Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.